Xbryk Disease Interactions
There are 2 disease interactions with Xbryk (denosumab).
Denosumab (applies to Xbryk) hypocalcemia
Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypoparathyroidism, Thyroid Disease, Renal Dysfunction
Preexisting hypocalcemia must be corrected prior to initiating treatment with denosumab. Caution should be exercised in patients predisposed to hypocalcemia and any disturbances of mineral metabolism, such as history of hypoparathyroidism, thyroid or parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or dialysis. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) are highly recommended within 14 days of denosumab injection. It is important to maintain calcium levels with adequate calcium and vitamin D supplementation.
Denosumab (applies to Xbryk) immunosuppression
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency
Denosumab should be used with caution in patients with impaired immune systems or taking concomitant immunosuppressant agents as they may be at increased risk for serious infections.
Switch to professional interaction data
Xbryk drug interactions
There are 306 drug interactions with Xbryk (denosumab).
Report options
More about Xbryk (denosumab)
- Check interactions
- Compare alternatives
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous bone resorption inhibitors
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Prolia
Prolia (denosumab) is an injection that is administered subcutaneously (under the skin) once every ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Reclast
Reclast (zoledronic acid) is used to treat osteoporosis in women after menopause and also to treat ...
Zometa
Zometa is used to treat high blood levels of calcium caused by cancer and multiple myeloma. Learn ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Xgeva
Xgeva prevents bone fractures and other skeletal conditions in people with multiple myeloma, and is ...
Aclasta
Aclasta (zoledronic acid) inhibits the release of calcium from bones and is used to treat Paget's ...
Jubbonti
Jubbonti (denosumab-bbdz) is an injection that is administered subcutaneously (under the skin) once ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.